1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101
    Meeting Abstract

    Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Miyake, H.; Oya, M.; Albiges, L.; Fujii, Y.; Umeyama, Y.; Wang, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F. A.; Goodman, O. B.; Oudard, S.; Steuber, T.; Suzuki, H.; Wu, D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Development and validation of circulating tumor cell (Epic Sciences) enumeration as a prognostic biomarker in men with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Scher, H. I.; Armstrong, A. J.; Schonhoft, J. D.; Gill, A.; Zhao, J.; Barnett, E.; Carbone, E.; Lu, J.; Antonarakis, E. S.; Luo, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC)
    Meeting Abstract

    Rathkopf, D. E.; Chi, K. N.; Olmos, D.; Cheng, H. H.; Agarwal, N.; Graff, J. N.; Sandhu, S. K.; Hayreh, V.; Lopez-Gitlitz, A.; Francis, P. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Single cell RNA sequencing of upper tract urothelial carcinoma to reveal significant heterogeneity of the tumor and immune microenvironment
    Meeting Abstract

    Reisz, P.; Tracey, A.; Kuo, F.; Thomas, J.; Clinton, T. N.; Lenis, A. T.; Truong, H.; Nagar, K.; Bochner, B. H.; Pietzak, E. J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Ryan, C. J.; VanderWeele, D. J.; Heller, G.; Lewis, L. D.; Watt, C.; Chen, R. C.; Grubb, R.; Hahn, O. M.; Beltran, H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Powles, T.; Rosenberg, J. E.; Sonpavde, G.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Wu, C.; Campbell, M. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)
    Meeting Abstract

    Rappold, P. M.; Silagy, A. W.; Kuo, F.; Marker, M.; Reising, A.; Millholland, J.; Russo, P.; Coleman, J.; Voss, M. H.; Chan, T. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR) - A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth
    Meeting Abstract

    Pouliot, F.; Gorin, M. A.; Rowe, S. P.; Saperstein, L.; Josephson, D.; Carroll, P. R.; Wong, J. Y. C.; Pantel, A. R.; Cho, S. Y.; Gage, K. L.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer
    Meeting Abstract

    Patel, V. G.; Zhong, X.; Shah, N. J.; Martina, L. P.; Hawley, J.; Lin, E.; Gartrell, B. A.; Febles, V. R. A.; Wise, D. R.; Qin, Q.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save